Article Per Year (5 Year)
p-Index From 2020 - 2025
2.162
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences Medical Journal of Indonesia Indonesian Journal of Cancer Universa Medicina Jurnal Respirologi Indonesia Jurnal Ilmu Kefarmasian Indonesia Jurnal Respirasi (JR) JURNAL PENELITIAN KEPERAWATAN MEDIK Respiratory Science Cermin Dunia Kedokteran Indonesian Journal of Cancer eJournal Kedokteran Indonesia
Elisna Syahruddin
Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Indonesia
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Earth & Planetary Sciences Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 25 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 25 Documents
Search

 1   2   3 
Hematologic Paraneoplastic Syndrome in Newly Diagnosed Patients with Lung Cancer Andika Chandra Putra; Steven Jonathan; Wira Winardi; Elisna Syahruddin
Jurnal Respirasi Vol. 9 No. 1 (2023): January 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.1.2023.18-29

Abstract

Introduction: Lung cancer could have signs and symptoms generated by paraneoplastic syndromes. This study aimed to describe and analyze hematologic paraneoplastic syndrome in patients with lung cancer in Indonesia. Methods: This was a cross-sectional analytic study conducted in Persahabatan National Respiratory Referral Hospital, Jakarta, between September 2018 and February 2019, on all newly diagnosed patients with lung cancer whose diagnosis was established and who fulfilled the inclusion and exclusion criteria. Results: The mean age of subjects was 56.7 ± 11.4 years old. Most subjects were male, had normal nutritional status (42.6%), had a smoking history (75%), and had a moderate Brinkman Index (BI) value (52%). The most common type of histology was squamous cell carcinoma (SCC) (39.7%), with advanced stage (83.8%) and performance status <2 (94.1%). Paraneoplastic anemia was 40.4%, associated with poor nutritional status and commonly normocytic normochromic anemia. The proportion of paraneoplastic leukocytosis was 39%, associated with males and smoking history. The proportion of paraneoplastic neutrophilia was 51.5%, and it was related to males, smoking history, and SCC histology type. Paraneoplastic hypereosinophilia and thrombocytosis proportions were 2.9% and 18.4%, respectively. The proportion of paraneoplastic hypercoagulability was 91.2%, which was caused by the elevated D-dimer level. Conclusion: The most common hematologic paraneoplastic syndromes in patients with lung cancer were hypercoagulability, neutrophilia, and anemia. The low hemoglobin (Hb) level of paraneoplastic anemia was associated with low body mass index (BMI). Male and smoking history in lung cancer patients were associated with paraneoplastic leukocytosis and/or neutrophilia.
Indonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia Andarini, Sita; Santoso, Andintia Aisyah; Arfiansyah, Mochammad Aris; Syahruddin, Elisna; Zaini, Jamal; Putra, Andika Chandra; Kurniawan, Ferry Dwi; Ermayanti, Sabrina; Soeroso, Noni Novisari; Munir, Sri Melati; Infianto, Andreas; Setijadi, Ana Rima; Setyawan, Ungky Agus; Wulandari, Laksmi; Haryati, Haryati; Jasminarti, Ida Ayu; Hidayat, Moulid; Santoso, Arif
Jurnal Respirologi Indonesia Vol 44, No 4 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i4.884

Abstract

Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.
National Lung Cancer Screening: Recommended Age for Screening Ramadhaniah, Fariha; Suzanna, Evlina; Syahruddin, Elisna; Shalmont, Grace; Rahayu, Pradnya Sri
Indonesian Journal of Cancer Vol 18, No 4 (2024): December
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i4.1223

Abstract

Indonesia, as a developing country, faces a significant burden of lung cancer, with the incidence and mortality rates ranking third. Unfortunately, the majority of patients are diagnosed at advanced stages of the disease. Indonesia has implemented a national cancer control program; screening and early detection are part of this program, which needs firm criteria to restrict the high-risk population due to limited resources. This article aims to recommend age criteria for National Lung Cancer Screening based on cancer registry data. We explore lung cancer screening policies across various countries, discuss the extent of the lung cancer burden and smoking prevalence as factors in determining age criteria for screening. Lung cancer is coded using ICD-O, third edition, C33–C34, and the incidence data were obtained from the Jakarta cancer registry. Data on the prevalence of smoking were obtained from national surveys and other research. Our review suggests that lung cancer screening should start at 35 years old, considering the distribution of lung cancer, the prevalence of smoking in Indonesia, as well as the carcinogenesis process of an individual when they start smoking.
Post-Market in vitro bioequivalence study of innovator and generic Gefitinib tablets: evaluation of JKN medicine quality Nurhayati, Fitri; Anggriani, Yusi; Syahruddin, Elisna; Andalucia, Rizka; Ath-Thobari, Jarir; Mulatsari, Esti
JURNAL ILMU KEFARMASIAN INDONESIA Vol 22 No 1 (2024): JIFI
Publisher : Faculty of Pharmacy, Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v22i1.1593

Abstract

Gefitinib is one of Tyrosine Kinase Inhibitors (TKIs), as first line therapy for Non-Small Cell Lung Cancer (NSCLC) with positive EGFR mutation. Gefitinib started to be accommodated in Jaminan Kesehatan Nasional (JKN) insurance in 2015 with the innovator gefitinib and was replaced by a generic product in middle of 2021. This research was conducted to see whether the quality of generic gefitinib equivalent to the innovator through post-market in vitro bioequivalence test. Assay method refers to previous research by Sandhya et al 2013 wih High Performance Liquid Chromatography (HPLC), while the dissolution test method is in accordance with the Food and Drug Association (FDA) 2010. We collected innovator from the official distributor and 3 batches (all batches that have been used in JKN program) of generic product from hospitals where lung cancer therapy services were provided. We evaluated the dissolution profile with similarity and unsimilarity factors and assess based on standard specification of dissolution profile that informed in innovator’s BPOM-approved brochure (avarage of 6 samples > 85% and no individual result < 75% at 45 minutes). The assay results met the requirements of ± 5% of what is stated on the label. Although dissolution profile of generic and innovator were not equal through difference and similarity factors calculation, but one batch of generics met dissolution profile standard of innovator. So, both generic and innovator drug met the standards of assay and dissolution, even though the dissolution profile were not equivalent.
ALK and PD-L1 Expression in Non-Small Cell Lung Cancer through Immunohistochemical Assays in Indonesia Syahruddin, Elisna; Sayekti, Mutia A.; Yuliyanti, Sayekti; Thabrany, Hasbullah; Nurmadani, Labbaika
Jurnal Respirologi Indonesia Vol 45 No 3 (2025)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v45i3.794

Abstract

Background: Advanced therapies for non-small cell lung carcinoma (NSCLC), such as targeted therapy and immunotherapy, are available; however, their use depends on biomolecular testing. In the Indonesian context, EGFR testing is covered by the national health insurance (JKN). According to the Indonesian Clinical Guideline for Lung Cancer, if the EGFR test is negative, further testing, including ALK and PD-L1 immunohistochemistry, is required. Nevertheless, the JKN does not currently cover ALK and PD-L1 IHC tests, which restricts access to the appropriate therapies. This study aims to determine the positivity rates of ALK and PD-L1 IHC tests. Method: This study employs a cross-sectional approach to analyze 2,553 ALK and PD-L1 IHC tests conducted from 2019 to 2023, sourced from four major provinces in Indonesia Results: The positivity of ALK IHC tests is 8% with a median age of 52 years. The positivity rate for PD-L1 IHC in all patients is 49%, while based on the tumour proportion score (TPS), TPS ≥50% is 17% and TPS 1-49% is 32%. ALK positivity correlates with age and female gender (P<0.001 and P=0.006). Conversely, PD-L1 positivity was significantly associated with cancer type (P=0.008). Conclusion: ALK positivity in NSCLC in Indonesia is relatively high (8%), with a relatively young median age of 52 years and is predominantly found in females. PD-L1 positivity does not significantly differ by gender and age, but positively correlates with adenocarcinoma cancer type.
Co-Authors Abul A'la Al Maududi AHMAD HUDOYO Ahmad Hudoyo Ahmad Hudoyo Aldri Frinaldi Alma Thahir Pulungan Ana Rima Ana Rima Setijadi Andalucia, Rizka Andarini, Sita Andi Yasmon Andreas Infianto Anna Rozaliyani Annisa Dian Harlivasari Anwar Jusuf Anwar Jusuf Arfiansyah, Mochammad Aris Aria Kekalih Arif Faisal ARIF R HANAFI ARIF R HANAFI, ARIF R Arif Santoso Arif Santoso Ath-Thobari, Jarir AZIZA G ICKSAN AZIZA G ICKSAN, AZIZA G Aziza Icksan Aziza Icksan Budiman Bela Denny Grecius Siregar Dian Cahyadi Dian Yulianti Ermayanti, Sabrina Ermayanti, Sabrina Erni Mudhiati EVLINA SUZANNA, EVLINA Fariz, Nurwidya Feni Fitriani Fera Ibrahim Ferry Dwi Kurniawan Findra Setianingrum Fitri Nurhayati GRACE SHALMONT, GRACE Haryati Haryati Haryati Haryati Hasbullah Thabrany Heriawaty Hidajat Heriawaty Hidajat, Heriawaty Hidayat, Moulid Ida Ayu Jasminarti Infianto, Andreas Jasminarti, Ida Ayu Kurniawan, Ferry Dwi Laksmi Wulandari Lia G. Partakusuma Lisnawati Lisnawati Melva Louisa Mia Elhidsi Mulatsari, Esti Mulyati Tugiran Nathaniel Aditya Noni Novisari Soeroso Nurmadani, Labbaika PRADNYA SRI RAHAYU, PRADNYA SRI Putra, Andika Chandra Rahmat Hidayat Ramadhaniah, Fariha Rianyta Rianyta Ridhawati Sjam Rita Khairani Robiatul Adawiyah Romi Baginta Santoso, Andintia Aisyah Sarah Fitriani Sayekti, Mutia A. Setiaputra Setiaputra Setyawan, Ungky Agus Shanty R. Kusumawardani Sita Andarini Sita Andarini Sita Andarini Soehardiman, Dicky Solly Aryza Sri Melati Munir Sri Melati Munir Steven Jonathan Tamam Anugrah TAMSIL Vivian Soetikno Winnugroho Wiratman, Manfaluthy Hakim, Tiara Aninditha, Aru W. Sudoyo, Joedo Prihartono Wira Winardi Yayi DB Susanto Yopi Simargi Yopi Simargi, Yopi Yuliyanti, Sayekti Yusi Anggriani Zahrah Annisa Zaini, Jamal